Document is current
Any future updates will be listed below
-
Authors
Aksentijevic, Dunja https://orcid.org/0000-0002-8480-6727
Sedej, Simon https://orcid.org/0000-0002-4419-6821
Fauconnier, Jeremy
Paillard, Melanie https://orcid.org/0000-0002-4912-4915
Abdellatif, Mahmoud https://orcid.org/0000-0002-5042-9054
Streckfuss-Bömeke, Katrin https://orcid.org/0000-0001-5137-7228
Ventura-Clapier, Renée
van der Velden, Jolanda https://orcid.org/0000-0001-5224-5788
de Boer, Rudolf A. https://orcid.org/0000-0002-4775-9140
Bertero, Edoardo
Dudek, Jan
Sequeira, Vasco https://orcid.org/0000-0002-9192-7674
Maack, Christoph https://orcid.org/0000-0003-3694-4559
- License Information
-
More Information
Article History
Accepted: 2 May 2025
First Online: 22 June 2025
Competing interests
: D.A. reports a research agreement with AstraZeneca. S.S. and M.A. hold a patent related to the cardiometabolic effects of nicotinamide and spermidine. M.P. reports a collaborative study with Boehringer Ingelheim. K.S.-B. has received grants from BionTech and Novartis and has received speaker’s honoraria from Novartis. R.A.d.B. has had speaker engagements with and/or received fees from and/or served on an advisory board for Abbott, AstraZeneca, Bristol Myers Squibb, NovoNordisk, Roche and Zoll; he has received travel support from Abbott and NovoNordisk, and his institution has received research grants and/or fees from Abbott, Alnylam, AstraZeneca, Bristol Myers Squibb, NovoNordisk and Roche; V.S. has received research funding from Bristol Myers Squibb. C.M. is an advisory board member or speaker for Amgen, AstraZeneca, Bayer, Berlin Chemie, Boehringer Ingelheim, Bristol Myers Squibb, Cytokinetics, Edwards, Lilly, Novartis, NovoNordisk and Servier. The other authors declare no competing interests.
